Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial 2022 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 196, no 2, p. 437-440Article in journal, Letter (Other academic) Published

Abstract [en]

n/a

Place, publisher, year, edition, pages

WILEY , 2022. Vol. 196, no 2, p. 437-440

Keywords [en]

Idelalisib; relapsed; refractory DLBCL; transformed lymphoma

Identifiers

URN: urn:nbn:se:liu:diva-178937DOI: 10.1111/bjh.17792ISI: 000688230400001PubMedID: 34435356OAI: oai:DiVA.org:liu-178937DiVA, id: diva2:1591294

Note

Funding Agencies|Gilead SciencesGilead Sciences Funding Source: Medline

Available from: 2021-09-06 Created: 2021-09-06 Last updated: 2022-09-28Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor

Lagerlöf, Ingemar

By organisation

Department of Health, Medicine and Caring SciencesFaculty of Medicine and Health Sciences

In the same journal

British Journal of Haematology

Search outside of DiVA

GoogleGoogle ScholarTotal: 35 hits